23andMe has a total of 345 patents globally, out of which 148 have been granted. Of these 345 patents, more than 68% patents are active. The United States of America is where 23andMe has filed the maximum number of patents, followed by Canada and Europe (EPO). Parallelly, the United States of America seems to be the main focused R&D centre and also is the origin country of 23andMe.
23andMe was founded in 2006. The company is a healthcare technology company that sells DNA testing kits directly to consumers by mail. Customers use these kits to learn about their genetic ancestry, traits, and potential health risks. The company has two main areas of business: Consumer and Research Services and Therapeutics. Most of its revenue comes from the Consumer and Research Services segment.
Do read about some of the most popular patents of 23andMe,which have been covered by us in this article and also you can find 23andMe patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over 23andMe patent portfolio.
How many patents do the Founder and CEO of 23andMe have?
The Founder Anne Wojcicki (also CEO) have 74 patents, Linda Avey have 80 and Paul Cusenza have 0 patents.
How many patents does 23andMe have?
23andMe has a total of 345 patents globally. These patents belong to 58 unique patent families. Out of 345 patents, 235 patents are active.
How Many Patents did 23andMe File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | 23andMe Applications Filed | 23andMe Patents Granted |
| 2025 | – | 2 |
| 2024 | 18 | 12 |
| 2023 | 35 | 18 |
| 2022 | 32 | 17 |
| 2021 | 56 | 19 |
| 2020 | 20 | 15 |
| 2019 | 43 | 8 |
| 2018 | 11 | 4 |
| 2017 | 7 | 6 |
| 2016 | 10 | 3 |
How many 23andMe patents are Alive/Dead?
Worldwide Patents
How Many Patents did 23andMe File in Different Countries?
Countries in which 23andMe Filed Patents
| Country | Patents |
| United States of America | 243 |
| Canada | 9 |
| Europe (EPO) | 8 |
| Taiwan | 6 |
| Argentina | 6 |
| Hong Kong (S.A.R.) | 3 |
| China | 3 |
| Australia | 3 |
| Korea (South) | 3 |
| Japan | 3 |
| India | 3 |
| Brazil | 3 |
| Israel | 2 |
| Philippines | 2 |
| Viet Nam | 2 |
| Singapore | 2 |
| Chile | 2 |
| Indonesia | 2 |
| Mexico | 2 |
| Malaysia | 2 |
| South Africa | 2 |
| Colombia | 2 |
| Peru | 2 |
| Pakistan | 1 |
| Germany | 1 |
| Costa Rica | 1 |
| New Zealand | 1 |
Where are Research Centers of 23andMe Patents Located?
What key Technologies are covered by 23andMe Patents?
23andMe started by helping people understand their DNA. Over time, it expanded into drug discovery, using data and biology to develop new treatments. Its patent portfolio shows this shift, with strong focus areas like Data Processing, Bioinformatics, and Antibody Ingredients. It also explores AI/ML, Pharmaceuticals, and even Data Privacy—reflecting its growing role in personalized healthcare.
A key reflection of this innovation is Atos Medical’s expansive patent portfolio, which includes 33 design patent families—showcasing user-friendly, patient-centric product aesthetics—and 106 utility patent families spanning specialized domains. These cover Tracheostomy Tubes, Voice Prostheses, Adhesive Baseplates & Accessories, Heat & Moisture Exchangers dedicated innovations in areas like Tracheostoma Dilators, Cuff Pressure Controllers, and even Adaptive Cutlery for users with swallowing difficulties.
Among the standout innovations is US20250021583A1, which introduces a smart way to select groups of people for genetic studies—without risking anyone’s privacy. This system ensures researchers can find meaningful patterns in health data while keeping identities safe, a crucial step as more people choose to share their DNA.
Another notable development is US20250084172A1, focusing on special proteins that can bind to harmful substances in the body. These kinds of innovations open the door to future tools for detecting or treating diseases, showing how 23andMe’s work extends beyond ancestry into possible healthcare applications.
In the area of family discovery, US20250094495A1 offers a way to find connections between people stored in large databases. By analysing similarities in their genetic data, it helps users uncover distant relatives or build out their family tree—turning data into meaningful relationships.
On the technology front, US20220044761A1 outlines a system that uses past genetic and health data to predict risks for certain diseases. With machine learning at its core, it supports more personalized advice, helping people understand what their DNA might say about future health.
Rounding out the portfolio is USD985610S1, a design patent that protects the layout of a screen used to display complex genetic results. By focusing on clarity and user experience, it ensures that important health and ancestry information is easier for everyday users to read and act on.
The chart below distributes 23andMe’s patents filed in different countries based on the technology protected by the patents. It also represents the markets where 23andMe thinks it’s important to protect particular technology inventions.
R&D Focus: How 23andMe Research’s Focus Changed Over the Years?
10 Best 23andMe Patents
USD788123S1 is the most popular patent in the 23andMe portfolio. It has received 856 citations so far from companies like Ethicon, Salesforce, and Abbott.
Below is the list of 10 most cited patents of 23andMe:
| Publication Number | Citation Count |
| USD788123S1 | 856 |
| US8200509B2 | 277 |
| US20100169313A1 | 170 |
| US20100169262A1 | 141 |
| US8108406B2 | 131 |
| US20080228797A1 | 131 |
| US20080227063A1 | 125 |
| US7917438B2 | 115 |
| US20100169338A1 | 111 |
| US8589437B1 | 102 |
What Percentage of 23andMe US Patent Applications were Granted?
23andMe (Excluding its subsidiaries) has filed 223 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these, 122 have been granted, leading to a grant rate of 63.21%.
Below are the key stats of 23andMe patent prosecution at the USPTO.
Which Law Firms are managing US Patents for 23andMe?
| Law Firm | Total Applications | Success Rate |
| 23Andme Inc (Inhouse IP Dept) | 120 | 70.1% |
| Mcdonnell Boehnen Hulbert & Berghoff Llp | 91 | 53.85% |
| Fisherbroyles Llp | 9 | 100.00% |
| Glaxosmithkline | 2 | 0% |
| Weaver Austin Villeneuve & Sampson Llp | 1 | 0% |
One more thing: We have converted this entire analysis into PDF form that you can download and save for later reading (or sharing with your friends). You can download it using the form below:
